Want to see HK:0928 full AI Analyst Report?
Life Healthcare Group (0928) AI Stock Analysis
Life Healthcare Group
(HKEX:0928)
The score is held back primarily by weak and inconsistent cash generation despite a return to profitability, while very low leverage supports financial stability. Technicals are a positive contributor with the stock trading above major moving averages and moderately constructive momentum, but valuation is a meaningful headwind given the high P/E and lack of dividend support.
Life Healthcare Group (0928) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 120.28M
- Dividend Yield
- ―
- Average Volume (3M)
- 820.47K
- Price to Earnings (P/E)
- 65.0
- Beta (1Y)
- 0.53
- Revenue Growth
- 251.35%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 13
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Life Healthcare Group Business Overview & Revenue Model
Company Description
King International Investment Limited operates as a holding company, with its core activities focused on the provision of healthcare products and related services. The firm's business interests are diversified, also encompassing money lending and the...
How the Company Makes Money
Life Healthcare Group makes money mainly by providing healthcare services through its hospital operations. Its revenue model is largely service-based: (1) Patient service revenue: The group earns fees from hospital services delivered to patients, inc...
Life Healthcare Group Financial Statement Overview
Summary
Revenue rebounded sharply in 2026 and profitability turned positive, and the balance sheet is conservatively financed with very low leverage. However, operating and free cash flow have been negative in most years (including 2026), making cash conversion and earnings quality a key ongoing risk and limiting the overall financial score.
Income Statement
56NeutralBalance Sheet
78PositiveCash Flow
24Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.50M | 143.23M | 40.77M | 233.68M | 223.85M | 92.87M |
| Gross Profit | 19.52M | 25.37M | 12.73M | 37.79M | 12.05M | 13.75M |
| EBITDA | -10.00M | 9.63M | -12.31M | 27.69M | -26.72M | -29.18M |
| Net Income | -38.45M | 1.84M | -47.45M | 15.82M | -25.19M | -34.46M |
Balance Sheet | ||||||
| Total Assets | 357.20M | 385.17M | 286.36M | 336.13M | 264.27M | 302.94M |
| Cash, Cash Equivalents and Short-Term Investments | 591.00K | 531.00K | 309.00K | 473.00K | 17.79M | 37.40M |
| Total Debt | 2.11M | 7.86M | 2.37M | 5.71M | 6.73M | 422.00K |
| Total Liabilities | 122.40M | 146.96M | 63.72M | 70.08M | 31.27M | 39.56M |
| Stockholders Equity | 234.80M | 238.21M | 222.64M | 269.85M | 237.50M | 262.28M |
Cash Flow | ||||||
| Free Cash Flow | -59.15M | -13.36M | -322.00K | -32.32M | -134.69M | 96.85M |
| Operating Cash Flow | -59.15M | -13.36M | -322.00K | -32.32M | -134.48M | 96.86M |
| Investing Cash Flow | -51.00K | 0 | -51.00K | 1,000 | 94.86M | -67.83M |
| Financing Cash Flow | 53.61M | -614.00K | -1.18M | 17.39M | 27.40M | -830.00K |
Life Healthcare Group Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0928, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 1.01, below the 50-day MA of 0.85, and above the 200-day MA of 0.59, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 39.66 is Neutral, neither overbought nor oversold. The STOCH value of 19.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0928.
Life Healthcare Group Peers Comparison
Overall Rating
HK:183068Neutral- HK:092857Neutral
HK:386954Neutral
HK:239352Neutral
HK:213842Neutral
HK:388641Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1830 | 68Neutral | HKD 1.43B | 8.01 | 43.78% | 12.76% | -14.68% | -13.60% |
| HK:0928 | 57Neutral | HKD 360.83M | 65.00 | 0.78% | ― | 251.35% | ― |
| HK:3869 | 54Neutral | HKD 467.79M | -143.32 | -0.41% | ― | 3.16% | -101.02% |
| HK:2393 | 52Neutral | HKD 146.77M | -1.48 | -22.16% | ― | -28.07% | 47.54% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2138 | 42Neutral | HKD 645.94M | -1.61 | -25.36% | ― | -8.94% | -140.82% |
| HK:3886 | 41Neutral | HKD 1.10B | 78.09 | 0.48% | 1.10% | -3.26% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0928 | Life Healthcare Group | 0.65 | 0.14 | 27.95% | |
| HK:1830 | Perfect Medical Health Management Limited | 1.14 | -0.08 | -6.79% | |
| HK:2138 | EC Healthcare | 0.55 | -0.10 | -16.15% | |
| HK:2393 | Yestar Healthcare Holdings Co Ltd | 0.06 | -0.07 | -51.54% | |
| HK:3869 | Hospital Corporation of China Ltd | 3.38 | -2.61 | -43.49% | |
| HK:3886 | Town Health International Medical Group Ltd. | 0.16 | -0.11 | -40.07% |
Life Healthcare Group Corporate Events
King International Investment Cancels Rights Issue After Major Shareholders Breach Undertakings
King International Investment Limited has disclosed that two substantial shareholders, Mr. Wang Mengyao and Ms. Wei Yan, failed to honour their irrevocable and unconditional undertakings to subscribe for their entitled rights shares under a planned r...
King International Investment faces temporary non-compliance after independent director resigns
King International Investment Limited announced that independent non-executive director Lou Tao has resigned from the board and the Fund Management Committee, effective 13 October 2026, to pursue other business commitments. The company said Lou has n...
King International Investment Updates Board and Committee Structure
King International Investment Limited has announced an updated composition of its board of directors, effective 13 October 2026, naming two co-chairmen, Leng Yueyingtan and Wang Jun, alongside three other executive directors and two independent non-e...
King International Wins Shareholder Backing for Share Consolidation and Major Rights Issue
King International Investment Limited has secured shareholder approval for a share consolidation and a rights issue at an extraordinary general meeting held on 28 September 2026, with both resolutions passed by poll with 100% of the votes cast in fav...
King International Plans Share Consolidation and Major Rights Issue
King International Investment Limited has called an extraordinary general meeting for 28 September 2026 in Hong Kong, where shareholders will vote on consolidating every 10 existing shares into one new share with a higher par value. The move will als...
King International Investment Wins Unanimous Shareholder Backing at AGM
Shareholders of King International Investment Limited have unanimously approved all resolutions at the annual general meeting held on 4 September 2026 in Hong Kong. The meeting covered routine governance matters, including adoption of audited financi...
King International Investment Revises Timetable for Share Consolidation and Rights Issue
King International Investment Limited has postponed the despatch of its circular on a proposed share consolidation, change of board lot size and rights issue, moving the expected mailing date from 20 August 2026 to on or before 11 September 2026. The...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026